CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $1.04M |
| Net Income (Most Recent Fiscal Year) | $-298.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -27563.32% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -35.09% |
| Return on Assets (Trailing 12 Months) | -32.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.38 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.69 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 94.89M |
| Free Float | 89.20M |
| Market Capitalization | $4.79B |
| Average Volume (Last 20 Days) | 1.03M |
| Beta (Past 60 Months) | 0.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |